# A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT04176588** · PHASE3 · UNKNOWN · sponsor: **Everstar Therapeutics Limited** · enrollment: 341 (actual)

## Conditions studied

- Moderately to Severely Active Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04176588
- **Lead sponsor:** Everstar Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-10
- **Primary completion:** 2024-07
- **Final completion:** 2024-10
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04176588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04176588, "A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04176588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*